Studying genetic and clinical features of multiple myeloma to understand how it behaves
Examines genetic and clinical features in adults with multiple myeloma, without testing a treatment.
Plain-language title generated from the registry record
Registry title: MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
Key facts
- Where
- Bologna, ItalySee the site
Where in Italy
- IRCCS AOU Policlinico Sant'OrsolaBologna, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT07582354
- Record updated
- 12 May 2026
- Original description
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.Read full original descriptionShow less
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance.
The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Inclusion: Age 18+; Signed CI for study partecipation and personal data processing; Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM).
Exclusion: None.